Fintel reports that on 2 November 2026, Canaccord Genuity downgraded their outlook for ResMed (DB:RME) from Buy to Hold. ResMed Inc. is a healthcare company based in the United States, primarily ...

The average one-year price target for ResMed (BMV:RMD) has been revised to MX$5,488.00 / share. This is an increase of 22.60% ...

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, ...

Resmed CMO Carlos Nunez discusses the Oura and Eight Sleep partnerships, consumer data opt-in trends, and the company's long-term sleep health strategy.

Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2026. “We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our ...

ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains ...

COWZ, QUAL, and SPHQ each aim to put you in higher-quality companies, but their portfolios barely recognize each other. Before you stack two of these funds for diversification, you need to see how ...

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never ...

In a report released today, Steven Wheen from Jarden maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, with a price target of A$38.70. Wheen covers the ...

Morgan Stanley analyst David Bailey maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh yesterday. The company’s shares closed today at A$33.46. Bailey ...

Amber Barkley is a writer and editor with over 10 years of experience in topics ranging from personal finance to marketing analytics to fiction. She found her niche ...

Diluted EPS was US$2.92 against US$2.37, on 143.4 million diluted shares against 146.9 million a year earlier. Sleep and Breathing Health product revenue rose to US$1.26 billion from US$1.17 billion, ...